Transcatheter Mitral Valve Replacement Attracts Interest From Edwards, Others
This article was originally published in The Gray Sheet
Leading the development of transcatheter mitral valve replacement therapies is one of Edwards Lifesciences’ strategic imperatives, the company explained during its recent investor conference. The potential market is large, but so are the technical hurdles. Medtronic and other smaller players are also taking steps.